Stemline Therapeutics Present Clinical Trial Results of Synthetic Peptide Vaccine for Brain Cancer at SNO Annual Meeting

Stemline Therapeutics (Nasdaq: STML ) announced today that clinical trial results of a synthetic peptide vaccine for brain cancer, now being developed as SL-701, will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in